Choose Licence

Oncology biosimilars are similar versions of oncology biologics that are manufactured by different companies and have been officially approved for cancer treatment. Biosimilars are cost-effective molecules with the same efficacy and potency as the original reference biologic. The relatively easy manufacturing of biosimilars and the license to manufacture biosimilars after the expiration of original reference biologic is acting in favor of the global oncology biosimilars market.
Scope of the Report:
This report focuses on the Oncology Biosimilars in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Cancer represents a massive burden on healthcare systems worldwide due to the high cost of treatment therapeutics. The patent expiry of several cancer therapeutics has allowed the entry of biosimilars, which are being incorporated into oncology treatment practices. Biosimilars are synthesized with the use of biologic components such as monoclonal antibodies, proteins, hormones, nucleic acids, colony stimulating factors, interleukins, and enzymes. The market offers huge growth opportunities for vendors because of the growing incidence of cancer. The clinical pipeline for cancer biosimilars is vast, featuring candidates in different stages of development. Around 30% of all the biosimilars that are awaiting the US FDA?s approval are monoclonal antibodies, including biosimilars of Avastin, MabThera, and Herceptin.
Factors like the arrival of new biosimilars to drive market growth during the forecast period. Unlike generic drugs, which have APIs that are identical to original drugs, biosimilars are similar to their originator biologic compounds. Biosimilars developed by different manufacturers differ from the original product as well as from each other. Since they are less expensive than biologics, patients will be able to afford and access biosimilars more easily than biologics. Rise in number of patent expiries, increase in prevalence of cancer, growing aging population, promising drug pipeline, need for cost-effective treatment, favorable government regulations are some of the key drivers promoting the growth of oncology biosimilars market.
The worldwide market for Oncology Biosimilars is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Biocon
Celltrion
Dr Reddy's Laboratories
F Hoffmann-La Roche
Mylan
Sandoz
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Breast Cancer
Blood Cancer
Colorectal Cancer
Non-Small
Cell Lung Cancer
Neutropenia
Others
Market Segment by Applications, can be divided into
Retail Pharmacies
Hospitals
There are 15 Chapters to deeply display the global Oncology Biosimilars market.
Chapter 1, to describe Oncology Biosimilars Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Oncology Biosimilars, with sales, revenue, and price of Oncology Biosimilars, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Oncology Biosimilars, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Oncology Biosimilars market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Oncology Biosimilars sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Other Reports by GlobalInfoResearch

An adhesion promoter is used as an additive or as a primer to promote adhesion of coatings, inks, or adhesives to the substrate of interest. An adhesion promoter usually has an affinity for the substrate and the applied coating, ink, or adhesive. Wit...

Pianoforte is a musical instrument in which felt-covered hammers, operated from a keyboard, strike the metal strings. It is commonly used for solo performances, ensemble, accompaniment and other performances, and it is very convenient for composing a...

Sodium petroleum sulfonate is a black brown translucent liquid that soluble in water. It is extracted from petroleum oil fraction by sulfonation, alcohol water extraction and sodium salt saponification, and then refined finally. It is usually produce...

Non-tire synthetic rubber is generally in term of all rubber products except product used in tires field, it covers a range of industrial, construction, medical and public health, sports and household and other rubber products, there are varieties of...

Chlorinated polyvinyl chloride pipe, more commonly known as ?CPVC pipe,? is a plumbing material made of highly durable thermoplastic, CPVC. Chlorinated polyvinyl chloride (CPVC) is white or light yellow, non-toxic loose grain or powder. It is a therm...